Optimizing KRAS Therapeutics for Non-Small Cell Lung Cancer.

Abstract

This review examines the evolving treatment landscape for <i>KRAS</i>-mutant non-small cell lung cancer (NSCLC), along with the significance of <i>KRAS</i> mutations. The development of <i>KRAS</i> G12C inhibitors, such as sotorasib and adagrasib, has changed the treatment landscape for patients with <i>KRAS</i>-mutant NSCLC, overcoming the long-standing challenge of targeting <i>KRAS</i>. However, acquired resistance remains a major hurdle, along with the need for effective therapies for non-G12C <i>KRAS</i> mutations. Ongoing research into next-generation inhibitors and combination strategies aim to improve the clinical outcomes of <i>KRAS</i>-mutant NSCLC patients.